Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Study Overview
=================
Brief Summary
-----------------
In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.

Official Title
-----------------
Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Conditions
-----------------
Esophageal Neoplasms

Intervention / Treatment
-----------------
* Radiation: definitive radiotherapy or definitive chemoradiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with esophageal cancer who received definitive radiotherapy (radiotherapy dose ≥50Gy) from 2015 to 2016 Age ≥ 18 The radiation field included primary esophageal tumor with or without lymph node metastasis Exclusion Criteria: Radiotherapy dose < 50Gy Palliative radiotherapy The radiation field are metastatic areas, such as bone, brain, adrenal gland, isolated metastatic lymph nodes, etc

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Definitive (chemo)radiotherapy<br> | Radiation: definitive radiotherapy or definitive chemoradiotherapy<br>* A total dose of radiation therapy should be more than 50Gy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 5 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess quality of life (QOL) | The EORTC QLQ-core 30 questionnaire is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations. | 5 year | 
| Costs of treatment | Financial burden, Whether medical insurance is affordable | 5 year | 
| Proportion of using chemotherapy or target therapy concurrently with radiotherapy | Medication | 2 month |